Sponsors generally recognize that older eCOA platforms use antiquated and/or have poorly integrated multiple disparate technologies.  The result is that these platforms require different devices, divide data flows, cost a lot to maintain, operate at slow speeds, and embed too many patches.  In addition to higher costs, this patchwork approach causes data errors and expanded timelines, not to mention the common need to manually merge data from these different platforms which leads to risk for more data errors, increases costs even more, and extends timelines considerably.

Because our platform has been built with a single code base and is accessible via a single downloadable application, it offers ultimate flexibility to sponsors looking to design traditional in clinic, remote or hybrid trials, using BYOD or fulfilled devices, collecting and monitoring all patient and clinician generated data, active (ePRO, eCLINRO, EMA) or passive.

The singular platform not only provides benefits around cost, speed and data security, but it also enables our teams to view clean data immediately, both separately and together comprehensively to further derive additional informed insights enhancing subject selection (adherence, consistently meeting entry criteria), precision measurement, meaningful change and separation from comparator treatments, and other longitudinal and contemporaneous insights.  The FDA has already set the precedent of acknowledging power in shorter, smaller trials based on the bolus of digital and other real-world data collected.